Telaprevir Twice Daily is Noninferior to Telaprevir Every 8 hrs for Patients with Chronic Hepatitis C.
- Buti, Maria
- Agarwal, Kosh
- Horsmans, Yves
- Sievert, William
- Janczewska, Ewa
- Zeuzem, Stefan
- Nyberg, Lisa
- Brown, Robert S
- Hezode, Christophe
- Rizzetto, Mario
- Parana, Raymundo
- De Meyer, Sandra
- De Masi, Ralph
- Luo, Donghan
- Bertelsen, Kirk
- Witek, James
DOIAbstract
Background & Aims We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis. Methods Patients were randomly assigned to groups treated with telaprevir 1125 mg twice daily or 750 mg every 8 hours plus peginterferon alfa-2a and ribavirin for 12 weeks; patients were then treated with peginterferon alfa-2a and ribavirin alone for 12 weeks if their level of HCV RNA at week 4 was <25 IU/mL or for 36 weeks if their level was higher. The primary objective was to demonstrate noninferiority of telaprevir twice daily versus every 8 hours in producing a sustained virological response 12 ...
Add to ORKG